Cantargia マネジメント

マネジメント基準チェック /24

Cantargiaの CEO はGoran Forsbergで、 Jun2014年に任命され、の在任期間は 10.42年です。の年間総報酬はSEK 5.40Mで、 44%給与と56%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.17%を直接所有しており、その価値はSEK 554.02K 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と4.1年です。

主要情報

Goran Forsberg

最高経営責任者

SEK 5.4m

報酬総額

CEO給与比率	44.0%
CEO在任期間	10.4yrs
CEOの所有権	0.2%
経営陣の平均在職期間	2.3yrs
取締役会の平均在任期間	4.1yrs

経営陣の近況

Recent updates

An Intrinsic Calculation For Cantargia AB (publ) (STO:CANTA) Suggests It's 47% Undervalued

May 31

Here's Why We're Not Too Worried About Cantargia's (STO:CANTA) Cash Burn Situation

May 02

Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?

Jan 10

CEO報酬分析

Cantargia の収益と比較して、Goran Forsberg の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-SEK 194m
Jun 30 2024	n/a	n/a	-SEK 228m
Mar 31 2024	n/a	n/a	-SEK 241m
Dec 31 2023	SEK 5m	SEK 2m	-SEK 280m
Sep 30 2023	n/a	n/a	-SEK 299m
Jun 30 2023	n/a	n/a	-SEK 293m
Mar 31 2023	n/a	n/a	-SEK 330m
Dec 31 2022	SEK 5m	SEK 2m	-SEK 372m
Sep 30 2022	n/a	n/a	-SEK 385m
Jun 30 2022	n/a	n/a	-SEK 419m
Mar 31 2022	n/a	n/a	-SEK 411m
Dec 31 2021	SEK 5m	SEK 2m	-SEK 367m
Sep 30 2021	n/a	n/a	-SEK 319m
Jun 30 2021	n/a	n/a	-SEK 255m
Mar 31 2021	n/a	n/a	-SEK 206m
Dec 31 2020	SEK 6m	SEK 2m	-SEK 173m
Sep 30 2020	n/a	n/a	-SEK 153m
Jun 30 2020	n/a	n/a	-SEK 139m
Mar 31 2020	n/a	n/a	-SEK 127m
Dec 31 2019	SEK 4m	SEK 2m	-SEK 111m
Sep 30 2019	n/a	n/a	-SEK 102m
Jun 30 2019	n/a	n/a	-SEK 98m
Mar 31 2019	n/a	n/a	-SEK 101m
Dec 31 2018	SEK 3m	SEK 1m	-SEK 91m
Sep 30 2018	n/a	n/a	-SEK 78m
Jun 30 2018	n/a	n/a	-SEK 68m
Mar 31 2018	n/a	n/a	-SEK 56m
Dec 31 2017	SEK 3m	SEK 1m	-SEK 60m

報酬と市場: Goranの総報酬 ($USD 495.43K ) は、 Swedish市場 ($USD 236.58K ) の同規模の企業の平均を上回っています。

報酬と収益: Goranの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Goran Forsberg (61 yo)

10.4yrs

在職期間

SEK 5,404,000

報酬

Mr. Goran Forsberg has been Independent Director at Guard Therapeutics International AB (publ) since May 2019. He has been the Chief Executive Officer at Cantargia AB (publ) since June 2014. Mr. Forsberg s...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Goran Forsberg	Chief Executive Officer	10.4yrs	SEK 5.40m	0.17% SEK 554.0k
Thoas Fioretos	Founder & Scientific Advisor	no data	SEK 355.00k	データなし
Marcus Järås	Founder & Scientific Advisor	no data	データなし	データなし
Kjell Sjöström	Founder	no data	データなし	データなし
Patrik Renblad	Chief Financial Officer	1.4yrs	データなし	データなし
David Liberg	Chief Scientific Officer	1.4yrs	データなし	データなし
Nina Valkama	Executive Assistant of Administration & Finance	2.9yrs	データなし	データなし
Dominique Tersago	Chief Medical Officer	2.3yrs	データなし	データなし
Antonius Berkien	Chief Business Officer	less than a year	データなし	データなし
Johanna Christensen	Financial Controller	2.9yrs	データなし	データなし

2.3yrs

平均在職期間

58.5yo

平均年齢

経験豊富な経営陣: CANTAの経営陣は経験豊富であると考えられます ( 2.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Gunnar Magnus Severus Persson	Independent Chairman of the Board	8.8yrs	SEK 854.00k	データなし
Damian Marron	Independent Director	3.5yrs	SEK 350.00k	データなし
Anders Martin-Lof	Independent Director	6.5yrs	SEK 473.00k	データなし
Magnus Nilsson	Independent Director	3.5yrs	SEK 342.00k	データなし
Flavia Borellini	Independent Director	4.1yrs	SEK 550.00k	データなし

4.1yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: CANTAの取締役会は経験豊富であると考えられます ( 4.1年の平均在任期間)。

Cantargia マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Cantargia AB (publ), Annual General Meeting, May 15, 2025

Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Insufficient new directors

Chief Executive Officer recently bought kr104k worth of stock

Chief Executive Officer recently bought kr103k worth of stock

Recent updates

Price target decreased by 24% to kr9.67

New major risk - Revenue and earnings growth

Cantargia AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Cantargia AB (publ), Annual General Meeting, May 15, 2025

New major risk - Share price stability

Cantargia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 169.910183 million.

Cantargia Presents Promising Preclinical Results on Nadunolimab with Antibody-Drug Conjugates At Major Immuno-Oncology Conference

Cantargia Reports New Results from Clinical Studies Investigating Nadunolimab in Several Forms of Cancer; Supporting Ongoing Strategies

Cantargia Reports New Positive Results on Biomarkers and Safety in CAN10 Phase 1 Clinical Study

Cantargia Announces the Publication of the Results Using Nadunolimab Combination Therapy in Advanced/Metastatic Pancreatic Cancer (PDAC) in the Scientific Journal Clinical Cancer Research

Cantargia AB (publ) to Report Q1, 2025 Results on May 13, 2025

Cantargia Announces New Data from Two Clinical Studies Strongly Support Nadunolimab Efficacy After Relapse on PD1-Inhibitors

Cantargia AB (publ) Reports Timelines for Nadunolimab Clinical Trials in Leukemia and Triple Negative Breast Cancer

Can Cantargia (STO:CANTA) Afford To Invest In Growth?

Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer

Cantargia AB (Publ) Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Insufficient new directors

Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

We're A Little Worried About Cantargia's (STO:CANTA) Cash Burn Rate

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition

Cantargia AB (publ) Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal

New minor risk - Share price stability

Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

Cantargia AB (publ) Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia

Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis

Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer

Price target decreased by 7.3% to kr12.67

Forecast to breakeven in 2026

New major risk - Financial position

Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab

Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy

Chief Executive Officer recently bought kr104k worth of stock

Cantargia Reports Phase I Clinical Progress in the CAN10 Project

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10

Chief Executive Officer recently bought kr103k worth of stock

New major risk - Revenue and earnings growth

New major risk - Financial position

Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Cantargia AB (publ), Annual General Meeting, May 23, 2024

New minor risk - Shareholder dilution

Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer

Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR

Cantargia AB (publ) Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant

Cantargia AB (publ)Expands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases

No longer forecast to breakeven

New major risk - Financial position

Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024

Cantargia AB (publ) Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10

New minor risk - Share price stability

Is Cantargia (STO:CANTA) In A Good Position To Deliver On Growth Plans?

Cantargia Publishes ASCO 2023 Poster on Promising Nadunolimab Efficacy in Non-Small Cell Lung Cancer

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Extends Development of Nadunolimab in Pancreatic Cancer with New Controlled Phase IIb Clinical Trial Following Strong Phase IIb Efficacy Results

We Think Cantargia (STO:CANTA) Can Afford To Drive Business Growth

Cantargia Appoints Patrik Renblad as Chief Financial Officer

Chief Executive Officer recently bought kr140k worth of stock

Cantargia AB (publ) Successfully Concludes Toxicity Study with Can10 Antibody Ahead of Phase I Clinical Trial Application

Cantargia AB (Publ) Announces Nomination Committee Appointments

Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?

Price target decreased to kr22.00

Cantargia's CAN10 Demonstrates Positive Activity in Systemic Sclerosis Models in New Data Presented At ACR Convergence 2022

Cantargia AB (Publ) Presents New Data At SITC 2022 Supporting Nadunolimab's Promising Antitumor Clinical Efficacy

Cantargia Reaches Recruitment Milestone and Focuses Nadunolimab Development on Upcoming Randomized Studies

Cantargia AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Cantargia Reports First Non-Squamous NSCLC Patient Treated with Nadunolimab, Keytruda® and Chemotherapy

マネジメント基準チェック /24